Ketamine Treatment Options in Canada (Updated 7/25)

Anesthetics and Analgesics in Children

NCT03427736

Recruiting

The purpose of this study is to characterize the pharmacokinetic (PK) and safety profile of anesthetics and analgesics in children and adolescents.

Gender:

ALL

Ages:

Between 0 years and 17 years

Trial Updated:

07/29/2025

Locations: Lucile Packard Children's Hospital, Stanford, California +12 locations

Conditions: Anesthesia, Pain

Register for Updates

Learn More ›

Chart Review of Patients Undergoing Ketamine Treatments for Depression

NCT07099235

Completed

The Ontario Ketamine and Infusion Centre (OKIC) is a CPSO-certified Level-II OHP and an outpatient centre for intravenous ketamine treatments for treatment-resistant depression. This retrospective, observational study aims to conduct a chart review on patients receiving ketamine in a naturalistic setting to develop our understanding of ketamine as an interventional approach for treatment-resistant depression.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/25/2025

Locations: Ontario Ketamine and Infusion Centre - Toronto Site, Mississauga, Ontario

Conditions: Depression - Major Depressive Disorder

Register for Updates

Learn More ›

Ketamine Sedation in the ICU (KANINE) RCT

NCT06767358

Not Yet Recruiting

Sedation is given to intensive care unit (ICU) patients to treat discomfort, anxiety, agitation, and to help facilitate care, particularly when they require a breathing tube. Sedation is very commonly used in the ICU with North American data showing almost 40% of ICU patients get sedation to help when they are requiring a breathing machine. Various medications can be given intravenously to provide sedation in the ICU but there are side-effects associated with each such as decreasing a patient's... Read More

Sedation is given to intensive care unit (ICU) patients to treat discomfort, anxiety, agitation, and to help facilitate care, particularly when they require a breathing tube. Sedation is very commonly used in the ICU with North American data showing almost 40% of ICU patients get sedation to help when they are requiring a breathing machine. Various medications can be given intravenously to provide sedation in the ICU but there are side-effects associated with each such as decreasing a patient's own drive to breathe, and delirium or acute confusion, both of which are associated with worse outcomes. Also, most drugs used for sedation don't treat pain. As a result, many ICU patients are also given narcotics for pain control which can result in tolerance, dependence, and withdrawal. Ketamine is a sedating medication that also treats pain and is often used in the Emergency Department and in the Operating Room but for whatever reason is not commonly used in the ICU. The investigators are proposing a study to examine the usefulness and safety of adding an intravenous infusion of ketamine to usual care in adult patients that are on a breathing machine in the ICU. Study Methods The KANINE study is being done at hospitals across Ontario, Canada. It is a randomized controlled trial which means patients will be randomized (akin to a coin flip) to receive ketamine or usual care without ketamine. The study will be blinded which means that neither patients or the doctors will know if the patient is getting ketamine or not, those that get randomized to usual care without ketamine will get an intravenous solution that looks the same as the ketamine infusion. This is important to make sure the results aren't biased in any way. The investigators will include adult ICU patients on a breathing machine who are early in their ICU admission. As most patients will be unconscious, the investigators will ask substitute decision makers (families or caregivers) of patients for informed consent prior to the study commencing. Regardless of whether patients get randomized to ketamine or not, the investigators will make sure that all patients will be adequately sedated and have their pain managed as per usual care. Setting This study will be performed in adult ICUs across Canada. Population The investigators will include adults admitted to the ICU on a breathing machine for at least 24 hours (and fewer than 3 days). The investigators will exclude patients if: (i) they were admitted with a brain bleed, traumatic brain injury, or stroke; (ii) Admitted with uncontrolled high blood pressure; (iii) if they have a history of schizophrenia; (iv) if they have very bad liver failure; (v) if they are palliative or only for comfort care; (vi) if they are receiving a medication that causes paralysis, sometimes used in patients with very bad lung disease; (vii) if they have a tracheostomy which means a whole in their neck that they breathe through; (viii) if they are allergic to ketamine; (ix) if they've had a liver transplant in the last month; (x) if they are pregnant or breast-feeding. Outcomes The investigators will follow all the study patients to see if their outcomes are different depending on whether they get randomized to ketamine or not. The investigators will capture how much time they are on the breathing machine, whether they survive or die, how long they stay in the ICU and whether they require a tracheostomy which is a procedure often done on patients who require the breathing machine over a prolonged period of time. The investigators will also capture how often they get delirious and for those that get delirious how long it lasts for. The investigators will capture how much of other sedating medications study patients use such as antipsychotics and benzodiazepines. The investigators will capture outcomes such as how often study patients get post-traumatic stress disorder after leaving the ICU and how well their pain relief is addressed during their ICU stay. Finally, the investigators will capture side effects related to ketamine or other sedating drug use. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

05/20/2025

Locations: St. Joseph's Healthcare Hamilton, Hamilton, Ontario +2 locations

Conditions: Mechanical Ventilation, Critically Ill Intensive Care Unit Patients

Register for Updates

Learn More ›

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064

Completed

The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) participants from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.

Gender:

ALL

Ages:

Between 18 years and 64 years

Trial Updated:

04/25/2025

Locations: Not set, Birmingham, Alabama +91 locations

Not set, Birmingham, Alabama

Not set, Little Rock, Arkansas

Not set, Garden Grove, California

Not set, Orange, California

Not set, San Diego, California

Not set, San Marcos, California

Not set, San Rafael, California

Not set, Bradenton, Florida

Not set, Miami, Florida

Not set, Orlando, Florida

Not set, Chicago, Illinois

Not set, Hoffman Estates, Illinois

Not set, Maywood, Illinois

Not set, Schaumburg, Illinois

Not set, Wichita, Kansas

Not set, Gaithersburg, Maryland

Not set, Boston, Massachusetts

Not set, Quincy, Massachusetts

Not set, Watertown, Massachusetts

Not set, Worcester, Massachusetts

Not set, Minneapolis, Minnesota

Not set, O'Fallon, Missouri

Not set, Saint Charles, Missouri

Not set, Omaha, Nebraska

Not set, New York, New York

Not set, Durham, North Carolina

Not set, Dayton, Ohio

Not set, Oklahoma City, Oklahoma

Not set, Media, Pennsylvania

Not set, Philadelphia, Pennsylvania

Not set, Lincoln, Rhode Island

Not set, Austin, Texas

Not set, Dallas, Texas

Not set, Houston, Texas

Not set, Woodstock, Vermont

Not set, Bothell, Washington

Not set, Middleton, Wisconsin

Not set, Aalst, Not set

Not set, Brugge, Not set

Not set, Brussel, Not set

Not set, Bruxelles, Not set

Not set, Gent, Not set

Not set, Hasselt, Not set

Not set, Heusden-Zolder, Not set

Not set, Liège, Not set

Not set, Spa, Not set

Not set, Yvoir, Not set

Not set, Belo Horizonte, Not set

Not set, Curitiba, Not set

Not set, Fortaleza, Not set

Not set, Passo Fundo, Not set

Not set, Porto Alegre, Not set

Not set, Rio de Janeiro, Not set

Not set, Santo André, Not set

Not set, Calgary, Alberta

Not set, Vancouver, British Columbia

Not set, Kingston, Ontario

Not set, Ottawa, Ontario

Not set, Toronto, Ontario

Not set, Montreal, Quebec

Not set, Parnu, Not set

Not set, Tallinn, Not set

Not set, Tartu, Not set

Not set, BESANCON Cedex, Not set

Not set, Clermont Ferrand, Not set

Not set, Douai, Not set

Not set, Issy-les-Moulineaux, Not set

Not set, La Tronche, Not set

Not set, Lille, Not set

Not set, Limoges, Not set

Not set, Montpellier Cedex 5, Not set

Not set, Nantes, Not set

Not set, Neuilly sur Marne, Not set

Not set, Nimes Cedex 9, Not set

Not set, Paris, Not set

Not set, Poitiers, Not set

Not set, Toulon, Not set

Not set, TOURS cedex 9, Not set

Not set, Budapest, Not set

Not set, Vác, Not set

Not set, Guadalajara, Not set

Not set, Leon, Not set

Not set, Mazatlan, Not set

Not set, Mexico City, Not set

Not set, Monterrey, Not set

Not set, San Luis Potosi, Not set

Not set, San Luis Potosí, Not set

Not set, Bratislava, Not set

Not set, Liptovsky Mikulas, Not set

Not set, Rimavska Sobota, Not set

Not set, Roznava, Not set

Not set, Svidnik, Not set

Conditions: Treatment-resistant Depression

Register for Updates

Learn More ›

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868

Completed

The purpose of this study is to assess the efficacy of intranasal esketamine plus an oral antidepressant compared with an oral antidepressant (active comparator) plus intranasal placebo in delaying relapse of depressive symptoms in participants with treatment-resistant depression (TRD) who are in stable remission after an induction and optimization course of intranasal esketamine plus an oral antidepressant.

Gender:

ALL

Ages:

Between 18 years and 64 years

Trial Updated:

04/25/2025

Locations: Not set, Birmingham, Alabama +159 locations

Not set, Birmingham, Alabama

Not set, Little Rock, Arkansas

Not set, Anaheim, California

Not set, Garden Grove, California

Not set, Glendale, California

Not set, Oakland, California

Not set, Orange, California

Not set, San Diego, California

Not set, San Marcos, California

Not set, San Rafael, California

Not set, Hartford, Connecticut

Not set, Bradenton, Florida

Not set, Gainesville, Florida

Not set, Miami, Florida

Not set, Orlando, Florida

Not set, Tampa, Florida

Not set, Atlanta, Georgia

Not set, Chicago, Illinois

Not set, Hoffman Estates, Illinois

Not set, Joliet, Illinois

Not set, Maywood, Illinois

Not set, Schaumburg, Illinois

Not set, Skokie, Illinois

Not set, Prairie Village, Kansas

Not set, Wichita, Kansas

Not set, Lake Charles, Louisiana

Not set, Baltimore, Maryland

Not set, Gaithersburg, Maryland

Not set, Boston, Massachusetts

Not set, New Bedford, Massachusetts

Not set, Quincy, Massachusetts

Not set, Watertown, Massachusetts

Not set, Worcester, Massachusetts

Not set, Rochester Hills, Michigan

Not set, Minneapolis, Minnesota

Not set, O'Fallon, Missouri

Not set, Saint Charles, Missouri

Not set, Omaha, Nebraska

Not set, New York, New York

Not set, Durham, North Carolina

Not set, Hickory, North Carolina

Not set, Oklahoma City, Oklahoma

Not set, Media, Pennsylvania

Not set, Philadelphia, Pennsylvania

Not set, Scranton, Pennsylvania

Not set, Lincoln, Rhode Island

Not set, Providence, Rhode Island

Not set, Arlington, Texas

Not set, Austin, Texas

Not set, Dallas, Texas

Not set, Houston, Texas

Not set, Charlottesville, Virginia

Not set, Waukesha, Wisconsin

Not set, Aalst, Not set

Not set, Brugge, Not set

Not set, Brussel, Not set

Not set, Heusden-Zolder, Not set

Not set, Liège, Not set

Not set, Yvoir, Not set

Not set, Belo Horizonte, Not set

Not set, Curitiba, Not set

Not set, Fortaleza, Not set

Not set, Goiania, Not set

Not set, Itapira, Not set

Not set, Passo Fundo, Not set

Not set, Porto Alegre, Not set

Not set, Rio de Janeiro, Not set

Not set, Santo André, Not set

Not set, Sao Jose do Rio Preto, Not set

Not set, São Paulo, Not set

Not set, Calgary, Alberta

Not set, Vancouver, British Columbia

Not set, Kingston, Ontario

Not set, Ottawa, Ontario

Not set, Toronto, Ontario

Not set, Montreal, Quebec

Not set, Brno, Not set

Not set, Hostivice, Not set

Not set, Klecany, Not set

Not set, Kutna Hora, Not set

Not set, Litomerice, Not set

Not set, Plzen, Not set

Not set, Prague, Not set

Not set, Praha 10, Not set

Not set, Praha 1, Not set

Not set, Praha 2, Not set

Not set, Praha 6, Not set

Not set, Strakonice 1, Not set

Not set, Parnu, Not set

Not set, Tallinn, Not set

Not set, Tartu, Not set

Not set, Clermont Ferrand, Not set

Not set, Douai, Not set

Not set, Nantes, Not set

Not set, Nimes Cedex 9, Not set

Not set, Paris, Not set

Not set, Poitiers, Not set

Not set, Toulon, Not set

Not set, Berlin, Not set

Not set, Cham, Not set

Not set, Gelsenkirchen, Not set

Not set, Halle (Saale), Not set

Not set, Mainz, Not set

Not set, Mittweida, Not set

Not set, Pfaffenhofen, Not set

Not set, Prien, Not set

Not set, Balassagyarmat, Not set

Not set, Budapest, Not set

Not set, Debrecen, Not set

Not set, Gyor, Not set

Not set, Pecs, Not set

Not set, Sopron, Not set

Not set, Szeged, Not set

Not set, Szekszárd, Not set

Not set, Vác, Not set

Not set, Guadalajara, Not set

Not set, Leon, Not set

Not set, Mexico City, Not set

Not set, Monterrey, Not set

Not set, San Luis Potosi, Not set

Not set, San Luis Potosí, Not set

Not set, Belchatow, Not set

Not set, Bialystok, Not set

Not set, Bydgoszcz, Not set

Not set, Gdansk, Not set

Not set, Leszno, Not set

Not set, Lodz, Not set

Not set, Lublin, Not set

Not set, Pruszkow, Not set

Not set, Torun, Not set

Not set, Tuszyn, Not set

Not set, Warszawa, Not set

Not set, Bratislava, Not set

Not set, Liptovsky Mikulas, Not set

Not set, Rimavska Sobota, Not set

Not set, Roznava, Not set

Not set, Svidnik, Not set

Not set, Alcorcón, Not set

Not set, Barcelona, Not set

Not set, Palma, Not set

Not set, Pamplona, Not set

Not set, Ponferrada, Not set

Not set, Sabadell, Not set

Not set, Salamanca, Not set

Not set, Vitoria Gasteiz, Not set

Not set, Lund, Not set

Not set, Skovde, Not set

Not set, Solna, Not set

Not set, Stockholm, Not set

Not set, Adana, Not set

Not set, Ankara, Not set

Not set, Bursa, Not set

Not set, Denizli, Not set

Not set, Istanbul, Not set

Not set, Izmir, Not set

Not set, Kucukcekmece/Istanbul, Not set

Not set, Manisa, Not set

Not set, Oanakkale, Not set

Not set, Sakarya, Not set

Not set, Samsun, Not set

Conditions: Depressive Disorder, Treatment-Resistant

Register for Updates

Learn More ›

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

NCT02782104

Completed

The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: Not set, Birmingham, Alabama +176 locations

Not set, Birmingham, Alabama

Not set, Little Rock, Arkansas

Not set, Garden Grove, California

Not set, Glendale, California

Not set, Oakland, California

Not set, Orange, California

Not set, San Diego, California

Not set, San Rafael, California

Not set, Hartford, Connecticut

Not set, New Haven, Connecticut

Not set, Gainesville, Florida

Not set, Miami, Florida

Not set, Orlando, Florida

Not set, Atlanta, Georgia

Not set, Chicago, Illinois

Not set, Hoffman Estates, Illinois

Not set, Joliet, Illinois

Not set, Maywood, Illinois

Not set, Skokie, Illinois

Not set, Iowa City, Iowa

Not set, Wichita, Kansas

Not set, Lake Charles, Louisiana

Not set, Shreveport, Louisiana

Not set, Baltimore, Maryland

Not set, Gaithersburg, Maryland

Not set, Boston, Massachusetts

Not set, New Bedford, Massachusetts

Not set, Watertown, Massachusetts

Not set, Worcester, Massachusetts

Not set, Rochester Hills, Michigan

Not set, O'Fallon, Missouri

Not set, Saint Charles, Missouri

Not set, Omaha, Nebraska

Not set, Cedarhurst, New York

Not set, New York, New York

Not set, Staten Island, New York

Not set, Hickory, North Carolina

Not set, Cincinnati, Ohio

Not set, Oklahoma City, Oklahoma

Not set, Allentown, Pennsylvania

Not set, Media, Pennsylvania

Not set, Philadelphia, Pennsylvania

Not set, Lincoln, Rhode Island

Not set, Providence, Rhode Island

Not set, Charleston, South Carolina

Not set, Austin, Texas

Not set, Dallas, Texas

Not set, Houston, Texas

Not set, Wichita Falls, Texas

Not set, Charlottesville, Virginia

Not set, Waukesha, Wisconsin

Not set, Banfield, Not set

Not set, Ciudad Autonoma de Buenos Aires, Not set

Not set, Ciudad Autónoma De Buenos Aires, Not set

Not set, Cordoba, Not set

Not set, La Plata, Not set

Not set, Mendoza, Not set

Not set, Rosario, Not set

Not set, Caulfield, Not set

Not set, Elizabeth Vale, Not set

Not set, Frankston, Not set

Not set, Vienna, Not set

Not set, Aalst, Not set

Not set, Brugge, Not set

Not set, Brussel, Not set

Not set, Heusden-Zolder, Not set

Not set, Liège, Not set

Not set, Yvoir, Not set

Not set, Belo Horizonte, Not set

Not set, Curitiba, Not set

Not set, Fortaleza, Not set

Not set, Passo Fundo, Not set

Not set, Porto Alegre, Not set

Not set, Recife, Not set

Not set, Rio de Janeiro, Not set

Not set, Sao Bernardo do Campo, Not set

Not set, Sao Paulo, Not set

Not set, Bourgas, Not set

Not set, Kardzhali, Not set

Not set, Pazardzhik, Not set

Not set, Pleven, Not set

Not set, Plovdiv, Not set

Not set, Rousse, Not set

Not set, Sofia, Not set

Not set, Varna, Not set

Not set, Vancouver, British Columbia

Not set, Kingston, Ontario

Not set, Ottawa, Ontario

Not set, Toronto, Ontario

Not set, Brno, Not set

Not set, Plzen, Not set

Not set, Prague, Not set

Not set, Praha 10, Not set

Not set, Praha 2, Not set

Not set, Praha 6, Not set

Not set, Tallinn, Not set

Not set, Tartu, Not set

Not set, Kuopio, Not set

Not set, Clermont-Ferrand Cedex 1, Not set

Not set, Douai, Not set

Not set, Nantes, Not set

Not set, Nîmes, Not set

Not set, Paris, Not set

Not set, Poitiers Cedex, Not set

Not set, Toulon Cedex, Not set

Not set, Berlin, Not set

Not set, Bochum, Not set

Not set, Mainz, Not set

Not set, Mittweida, Not set

Not set, Oranienburg, Not set

Not set, Pfaffenhofen, Not set

Not set, Budapest, Not set

Not set, Debrecen, Not set

Not set, Gyor, Not set

Not set, Pecs, Not set

Not set, Sopron, Not set

Not set, Szekszárd, Not set

Not set, Vác, Not set

Not set, Gwangju, Not set

Not set, Seoul, Not set

Not set, Kaunas, Not set

Not set, Kuala Lumpur, Not set

Not set, Guadalajara, Not set

Not set, Leon, Not set

Not set, Mexico City, Not set

Not set, Mexico, Not set

Not set, Monterrey, Not set

Not set, San Luis Potosi, Not set

Not set, Belchatow, Not set

Not set, Bialystok, Not set

Not set, Bydgoszcz, Not set

Not set, Gdansk, Not set

Not set, Leszno, Not set

Not set, Lublin, Not set

Not set, Warszawa, Not set

Not set, Bratislava, Not set

Not set, Liptovsky Mikulas, Not set

Not set, Rimavska Sobota, Not set

Not set, Roznava, Not set

Not set, Svidnik, Not set

Not set, Cape Town, Not set

Not set, Pretoria, Not set

Not set, Welgemoed, Not set

Not set, Alcorcón, Not set

Not set, Barcelona, Not set

Not set, Bilbao, Not set

Not set, Madrid, Not set

Not set, Oviedo, Not set

Not set, Palma, Not set

Not set, Pamplona, Not set

Not set, Sabadell, Not set

Not set, Salamanca, Not set

Not set, Sant Boi de Llobregat, Not set

Not set, Torrevieja, Not set

Not set, Vitoria-Gasteiz, Not set

Not set, Zamora, Not set

Not set, Halmstad, Not set

Not set, Lund, Not set

Not set, Skövde, Not set

Not set, Stockholm, Not set

Not set, Kaohsiung, Not set

Not set, New Taipei, Not set

Not set, Taichung, Not set

Not set, Taipei, Not set

Not set, Taoyuan, Not set

Not set, Adana, Not set

Not set, Ankara, Not set

Not set, Bursa, Not set

Not set, Istanbul, Not set

Not set, Kucukcekmece/Istanbul, Not set

Not set, Oanakkale, Not set

Not set, Samsun, Not set

Not set, Chesterfield, Not set

Not set, Derby, Not set

Not set, London, Not set

Not set, Northampton, Not set

Not set, Oxford, Not set

Conditions: Depressive Disorder, Treatment-Resistant

Register for Updates

Learn More ›

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03097133

Completed

The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.

Gender:

ALL

Ages:

Between 18 years and 64 years

Trial Updated:

04/25/2025

Locations: University of California San Diego/Psychiatry, San Diego, California +60 locations

University of California San Diego/Psychiatry, San Diego, California

Sharp Mesa Vista Hospital, San Diego, California

University of Conneticut School of Medicine, Farmington, Connecticut

University of Miami Health System, Miami, Florida

Innovative Clinical Research Inc, North Miami, Florida

University of South Florida, Tampa, Florida

Atlanta Behavioral Research, LLC, Atlanta, Georgia

Memorial Medical Center, Springfield, Illinois

Neuroscience Research Institute, Winfield, Illinois

Lake Charles Clinical Trials, Lake Charles, Louisiana

John Hopkins Hospital, Baltimore, Maryland

Altea Research Institute, Las Vegas, Nevada

The Zucker Hillside Hospital, Glen Oaks, New York

Stony Brook University Medical Center, Stony Brook, New York

University of North Carolina, Chapel Hill, North Carolina

University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio

East Tennessee State University, Johnson City, Tennessee

University of Wisconsin Medical Center, Madison, Wisconsin

Clínica Privada Banfield S.A, Banfield, Not set

Hospital Fleni, Ciudad de Buenos Aires, Not set

Sanatorio Prof. Leon S. Morra, Cordoba, Not set

Clinica Privada de Salud Mental Santa Teresa de Ávila, La Plata, Not set

Medical University Vienna MUV, Vienna, Not set

Klinikum Wels Grieskirchen, Wels, Not set

AZ Sint Jan Brugge Oostende AV, Brugge, Not set

UZ Gent, Gent, Not set

ARIADNE, Lede, Not set

Universidade Federal De Minas Gerais - Hospital das Clínicas, Belo Horizonte, Not set

Universidade Federal Do Ceara, Fortaleza, Not set

Instituto Bairral de Psiquiatria, Itapira, Not set

Hospital Universitario Professor Edgar Santos, Salvador, Not set

CEMEC - Centro Multidisciplinar de Estudos Clínicos, Santo Andre, Not set

Hospital Das Clinicas Da Faculdade De Medicina Da USP, São Paulo, Not set

St. Michael's Hospital, Toronto, Ontario

Institut universitaire en sante mentale de Montreal, Montréal, Quebec

Fakultni nemocnice Brno, Brno, Not set

Nemocnice s pol. Havirov, p.o., Havirov, Not set

Narodni ustav dusevniho zdravi, Klecany, Not set

Vseobecna Fakultní Nemocnice, Praha, Not set

Ústrední vojenské nemocnice Praha, Praha, Not set

Hôpital de Bohars, Bohars, Not set

CHRU Montpellier Hopital Lapeyronie, Montpellier, Not set

CHU Caremeau, Nimes, Not set

Hopital Sainte Anne, Paris, Not set

CHU Saint Etienne Hopital Nord, Saint-Priest en Jarez, Not set

CHU Toulouse, Toulouse, Not set

Republic Kaunas Hospital, Kaunas County, Not set

Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Not set

Vilnius Mental Health Center, Vilnius, Not set

Uniwersyteckie Centrum Kliniczne, Gdansk, Not set

Szpital Specjalistyczny im H Klimontowicza Oddzial Psychiatryczny, Gorlice, Not set

SPZOZ CSK UM w Lodzi Klinika Zaburzen Afektywnych i Psychotycznych, Lodz, Not set

Klinika Psychiatryczna WUM Mazowieckie Specjalistyczne Centrum Zdrowia im prof Jana Mazurkiewicza, Pruszkow, Not set

Hosp Univ Vall D Hebron, Barcelona, Not set

Inst. Internac. Neurociencias Aplicadas, Barcelona, Not set

Hosp. Univ. de Basurto, Bilbao, Not set

Clinica Univ. de Navarra, Pamplona, Not set

Bursa Sevket Yilmaz Research and Training Hospital, Bursa, Not set

Uludag University Medical Faculty, Bursa, Not set

Sisli Etfal Research Training Hospital, Istanbul, Not set

Samsun Psychiatric Hospital, Samsun, Not set

Conditions: Depressive Disorder, Major

Register for Updates

Learn More ›

Safety and Efficacy of Ketamine Intravenous Infusions in the Treatment of Fibromyalgia

NCT06916403

Active Not Recruiting

Previous studies of intravenous ketamine, which is a non-competitive N-methyl-D aspartate receptor antagonist, for fibromyalgia pain relief are limited to three studies. Two studies have focused on short-term pain relief of intravenous ketamine by measuring the patients' pain levels immediately before and after the infusion. Currently, existing studies used short-term infusions (30-40 minutes) of sub-anesthetic doses of ketamine for pain relief in fibromyalgia patients, whereas the Consensus Gui... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/31/2025

Locations: Wilderman Medical Clinic, Thornhill, Ontario

Conditions: Fibromyalgia

Register for Updates

Learn More ›

I-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: a Randomized, Midazolam-Controlled Clinical Trial

NCT06480500

Recruiting

Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years). Most people with depression experience thoughts of suicide and many will also plan and/or attempt suicide at some time in their life. There is an urgent need for new scalable treatments that can effectively reduce suicidality in people with depression. Cognitive behavioural therapy (CBT) reduces suicidal thoughts and behaviours, and can be de... Read More

Gender:

ALL

Ages:

Between 21 years and 65 years

Trial Updated:

03/26/2025

Locations: Toronto General Hospital, Toronto, Ontario +1 locations

Conditions: Major Depressive Disorder, Suicide, Treatment Resistant Depression

Register for Updates

Learn More ›

Understanding and Treating Suicidal Ideation with Ketamine

NCT06891300

Not Yet Recruiting

The goal of this clinical trial is to treat active suicidal ideation in individuals with Major Depressive Disorder (MDD) using ketamine and to understand suicidal ideation by examining biological mechanisms using magnetic resonance imaging (MRI), and psychological mechanisms through validated clinical scales and qualitative interviews. The main questions it aims to answer are: 1. Will ketamine will reduce suicidal ideation in a significant proportion of study participants? 2. Will reduction in... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

03/18/2025

Locations: Royal Ottawa Mental Health Centre, Ottawa, Ontario

Conditions: Suicidal Ideation, Major Depressive Disorder (MDD)

Register for Updates

Learn More ›

InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression

NCT06781697

Not Yet Recruiting

Depression is a common condition, with serious negative effects on the health and quality of life of those affected. While there are currently various medications which attempt to treat depression, they often take a long time to begin to work and do not work at all for many people. There is therefore a need for new treatments which work quickly and effectively. One such medication is called ketamine. Studies have shown that ketamine can treat symptoms of depression quickly. This quick action se... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/07/2025

Locations: Sunnybrook Health Sciences Centre, Toronto, Ontario

Conditions: Treatment Resistant Depression

Register for Updates

Learn More ›

Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression

NCT05177146

Completed

Bipolar disorder is characterized by manic episodes and episodes of extreme depressive feelings, also known as bipolar depression (BD). Although clinical data does not suggest significant differences in the severity of depressive symptoms between bipolar and unipolar depression, patients with BD are found to be more likely to experience suicidal ideation and suicide attempts. Innovative treatments for suicidality in patients with BD are needed to address tolerability and slow effect limitations... Read More

Gender:

ALL

Ages:

Between 24 years and 65 years

Trial Updated:

02/04/2025

Locations: Centre for Addiction and Mental Health, Toronto, Ontario

Conditions: Bipolar Disorder (BD), Suicidality

Register for Updates

Learn More ›

Ketamine Treatment Options in Canada

Match to Clinical Trials